Biomea Fusion Inc (BMEA) Stock Price, Quote & News

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle con...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 980 9099

Website: biomeafusion.com

Address:

1599 Industrial Road, San Carlos, United States

Pedross Feb. 3 at 9:11 PM

$BMEA Rinse & Repeat ,almost 50000 shares covered at the closed. They have been doing it for weeks now. Pushed price lower and come back and covered right at the close.

0 · Reply

Newcar Feb. 3 at 6:11 PM

$BMEA My goal is to buy at a fair price and it is currently still too high.👍

2 · Reply

LouKojak Feb. 3 at 5:14 PM

$BMEA if you have conviction in the play and see a weekly low, buy it. 🤑

0 · Reply

Newcar Feb. 3 at 4:15 PM

$BMEA Don't confuse apples with oranges. We're very far from having an approved drug here...and Jardiance's scope of application isn't just for diabetes, but also for heart failure. If there were any real hope of success here, it wouldn't be so small. It's the typical small-cap pump-and-dump.

0 · Reply

BobBijawklah Feb. 3 at 3:31 PM

$BMEA Lets compare Jardiance type 2 diabetes sales reflective of the SIDD . Jardiance had a peak sales of around 5 billion . sidd is approximately 20% of type two market . So lets say peak market cap around 1 billion if we capture 25% of that we are looking at approximately 250 million per year in annual sales. So that is approximately worth 4 dollars a share on approval. I am not factoring the plus ozempic and glp1 but will say that adds approximately 50 cents to a dollar at this stage in development. So as the second half of year approaches it would be plausible that we are in the 2.50-3.00 range pre data . post data if positive 3.50-5. Post data if SIDD is negative 50 cents to 1 dollar. Reasonable estimates take it to the bank

0 · Reply

Newcar Feb. 3 at 2:17 PM

$BMEA I'd like to buy some shares, but they're currently too expensive considering the company's current value, which I estimate isn't worth more than $50 million, or maybe even less. I'd like to buy them at around $0.80. I'll wait.

3 · Reply

Mr_GA Feb. 3 at 4:51 AM

$BMEA OVERNIGHT QUOTE

1 · Reply

slaykween Feb. 2 at 9:21 PM

$BMEA letting this go for now was a good move

1 · Reply

Apes_Strong Feb. 2 at 8:19 PM

$BMEA a JP Morgan analyst who should be investigated happens to choose BMEA to add to its short list WHILE the company is attenting and presenting at the JPMorgan biotech conference His reasons, funding concerns, while misquoting how much cash they have It’s transparent what happened here JP Morgan hedge funds with a 8 million share short position were at risk of the stock breaking out across $1.60 In steps compromised analyst Today was the last large chunk of the short covered Analysts like this need to be jailed not lauded

1 · Reply

10xMoonstocks Feb. 2 at 5:09 PM

$BMEA Where in the holy hell are you coming up with that number??? Just tossing something out to the wind?

0 · Reply

Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:00 AM EST - 22 days ago

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

Dec 17, 2025, 7:00 AM EST - 6 weeks ago

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 9, 2025, 6:35 PM EST - 7 weeks ago

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

Dec 5, 2025, 7:00 AM EST - 2 months ago

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 1, 2025, 4:10 PM EST - 2 months ago

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 1, 2025, 4:05 PM EST - 2 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Nov 24, 2025, 7:00 AM EST - 2 months ago

Biomea Fusion to Participate at Upcoming Investor Conferences

Nov 10, 2025, 7:00 AM EST - 3 months ago

Biomea Fusion to Participate at Jefferies London Healthcare Conference

Nov 5, 2025, 7:00 AM EST - 3 months ago

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

Nov 4, 2025, 4:05 PM EST - 3 months ago

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

Oct 30, 2025, 8:00 AM EDT - 3 months ago

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

Oct 27, 2025, 8:00 AM EDT - 3 months ago

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

Oct 23, 2025, 3:57 PM EDT - 3 months ago

Biomea Fusion, Inc. (BMEA) Presents at Citi's 2025 SMID Cap Biopharma Call Series Transcript

Oct 21, 2025, 7:05 PM EDT - 3 months ago

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

Oct 7, 2025, 12:05 PM EDT - 4 months ago

Biomea Fusion, Inc. - Special Call

Oct 7, 2025, 10:35 AM EDT - 4 months ago

Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study

Oct 7, 2025, 8:00 AM EDT - 4 months ago

Biomea Fusion Announces Pricing of Public Offering of Securities

Oct 6, 2025, 4:18 PM EDT - 4 months ago

Biomea Fusion Announces Proposed Public Offering of Securities

Oct 6, 2025, 4:03 PM EDT - 4 months ago

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Oct 1, 2025, 7:00 AM EDT - 4 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Sep 16, 2025, 7:00 AM EDT - 5 months ago

Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

Aug 5, 2025, 4:05 PM EDT - 6 months ago

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Jul 24, 2025, 7:00 AM EDT - 6 months ago

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Jun 23, 2025, 7:00 AM EDT - 8 months ago

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 7:00 AM EDT - 8 months ago

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Jun 18, 2025, 6:28 AM EDT - 8 months ago

Biomea Fusion Shares Fall After Pricing Underwritten Public Offering

Jun 17, 2025, 7:28 PM EDT - 8 months ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR

$Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025$

Jun 13, 2025, 6:45 AM EDT - 8 months ago

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

$Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia$

May 14, 2025, 4:05 PM EDT - 9 months ago

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

May 5, 2025, 4:05 PM EDT - 9 months ago

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

Apr 1, 2025, 4:01 PM EDT - 11 months ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 4:10 PM EDT - 11 months ago

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 25, 2025, 7:00 PM EDT - 11 months ago

Biomea Fusion Announces Leadership Transition

Mar 24, 2025, 8:30 AM EDT - 11 months ago

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Feb 27, 2025, 8:00 AM EST - 1 year ago

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Dec 17, 2024, 10:41 AM EST - 1 year ago

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Dec 17, 2024, 8:10 AM EST - 1 year ago

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Dec 16, 2024, 6:15 PM EST - 1 year ago

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Dec 12, 2024, 5:02 PM EST - 1 year ago

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

$Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia$

Dec 9, 2024, 4:01 PM EST - 1 year ago

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

$Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia$

Dec 6, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Nov 3, 2024, 11:00 AM EST - 1 year ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Oct 31, 2024, 11:00 AM EDT - 1 year ago

Biomea Fusion Inc Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 30, 2024, 4:00 PM EDT - 1 year ago

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Oct 29, 2024, 4:46 PM EDT - 1 year ago

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 29, 2024, 11:00 AM EDT - 1 year ago

An Investigation Has Been Launched Into Whether Biomea Fusion Inc Committed Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Pedross Feb. 3 at 9:11 PM

$BMEA Rinse & Repeat ,almost 50000 shares covered at the closed. They have been doing it for weeks now. Pushed price lower and come back and covered right at the close.

0 · Reply

Newcar Feb. 3 at 6:11 PM

$BMEA My goal is to buy at a fair price and it is currently still too high.👍

2 · Reply

LouKojak Feb. 3 at 5:14 PM

$BMEA if you have conviction in the play and see a weekly low, buy it. 🤑

0 · Reply

Newcar Feb. 3 at 4:15 PM

0 · Reply

BobBijawklah Feb. 3 at 3:31 PM

0 · Reply

Newcar Feb. 3 at 2:17 PM

3 · Reply

Mr_GA Feb. 3 at 4:51 AM

$BMEA OVERNIGHT QUOTE

1 · Reply

slaykween Feb. 2 at 9:21 PM

$BMEA letting this go for now was a good move

1 · Reply

Apes_Strong Feb. 2 at 8:19 PM

1 · Reply

10xMoonstocks Feb. 2 at 5:09 PM

$BMEA Where in the holy hell are you coming up with that number??? Just tossing something out to the wind?

0 · Reply

abdsamad Feb. 2 at 4:41 PM

$BMEA will soon fill 5.56 gap

0 · Reply

abdsamad Feb. 2 at 4:39 PM

$BMEA hammer at 30 min chart

0 · Reply

raulsan79trader Feb. 2 at 4:17 PM

$BMEA That was near. It's ok, I raise my rebuy order to $1.02 👀

0 · Reply

kogklasse Feb. 2 at 4:07 PM

$BMEA volume can end up high today. Something might be cooking. Remember that pro investors are not scared. They set a long term price target and an accumulation target. Then buy little by little continuously. That is why most retail investors get scared. Cause they do not have the capital firepower for this. You cannot time it. Had an average of 1.16, thought I was sitting comfortably, now I will buy soon again, looking for it to bottom out. Is that today?

0 · Reply

Newcar Feb. 2 at 3:51 PM

$BMEA With the next dilution, the greatest risk would be a reverse split. A reverse split would mean losing your entire investment. This company is still in first step, it needs a lot of money, and the current funds are sufficient for about a year. Everyone must make their own decisions, considering the risk.

2 · Reply

username0055 Feb. 2 at 3:42 PM

$BMEA Good grief

0 · Reply

BiomeaIR Feb. 2 at 3:40 PM

$BMEA Biomea Fusion continues to operate with a strong emphasis on financial discipline and efficient clinical development. Based on its most recent public disclosures, the company has cash runway extending into 2027, providing support for planned operating and clinical activities. This runway enables continued advancement of the Phase II icovamenib program and the Phase I study of BMF-650, while maintaining flexibility for upcoming milestones. Importantly, this position supports responsible execution and program continuity without compromising scientific rigor or strategic independence. Management remains focused on careful capital allocation and consistent delivery as development activities progress.

1 · Reply

Eternal_Optimist Feb. 2 at 3:07 PM

$BMEA Good Morning Folks! Certainly an active board with bears and bots currently. I am a clear eyed and critically thinking bull and see no material change in this company from a few weeks ago and higher share prices. The market is a voting machine and shorts are there also. As a few of us have reiterated no one can predict share prices in short term, however in long term they will reflect company fundamentals and eventually short sellers will peel back somewhat. I still own by 100K shares at 1.53 average and may add (or may not). Bulls are not obliged to sell or add just like bears. Yes it could go lower and folks may want to think about dollar cost averaging down… Wrt dilution, that is an option for raising capital always in public companies, however other partnerships etc can offer alternative paths. The company is acting ethically and consistently. The product pipeline moves forward. For the bears/bots, wish you well and let’s see where things go! Holding strong!

3 · Reply

Newcar Feb. 2 at 2:58 PM

$BMEA waiting 0,8$. Push this down👍👍👍

1 · Reply

10xMoonstocks Feb. 2 at 2:50 PM

$BMEA Don't worry, the disappearing Creisi is buying 750k shares, so that should make up for it!

0 · Reply

oldmanrizzer Feb. 2 at 2:49 PM

$BMEA Stop loss at 1.00 may hit today. Gotta take that risk on these penny stocks but also know when it's time to go.

1 · Reply

maildriver Feb. 2 at 1:50 PM

$BMEA So the CEO buys thousands of shares at 1.43 but doesn't buy any at 1.11 lol ok right

1 · Reply

Market Cap	79.19M
Revenue (ttm)	0.00
Net Income (ttm)	-138.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	842,771
Avg Vol	1,383,344
Day's Range	N/A - N/A
Shares Out	70.70M
Stochastic %K	14%
Beta	-0.16
Analysts	Strong Sell
Price Target	$7.00